{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T21:01:25Z","timestamp":1774904485523,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:00:00Z","timestamp":1584316800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:00:00Z","timestamp":1584316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s40264-020-00923-6","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T12:04:59Z","timestamp":1584360299000},"page":"669-675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Rates and Costs of Dispensing Naloxone to Patients at High Risk for Opioid Overdose in the United States, 2014\u20132018"],"prefix":"10.1007","volume":"43","author":[{"given":"Rachel E.","family":"Barenie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua J.","family":"Gagne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajinkya","family":"Pawar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian T.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,16]]},"reference":[{"key":"923_CR1","unstructured":"Centers for Disease Control and Prevention. Changes in Opioid Prescribing Practices. 2019. https:\/\/www.cdc.gov\/drugoverdose\/data\/prescribing\/prescribing-practices.html. Accessed 29 Jan 2020."},{"issue":"1","key":"923_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.su6501a1","volume":"65","author":"Centers for Disease Control and Prevention","year":"2016","unstructured":"Centers for Disease Control and Prevention. CDC guidelines for prescribing opioids for chronic pain\u2014United States, 2016. MMWR. 2016;65(1):1\u201349.","journal-title":"MMWR."},{"issue":"31","key":"923_CR3","first-page":"679","volume":"68","author":"GP Guy","year":"2019","unstructured":"Guy GP, et al. Vital signs: pharmacy-based naloxone dispensing\u2014United States, 2012\u20132018. MMWR. 2019;68(31):679\u201386.","journal-title":"MMWR."},{"issue":"5","key":"923_CR4","doi-asserted-by":"publisher","first-page":"e193209","DOI":"10.1001\/jamanetworkopen.2019.3209","volume":"2","author":"S Follman","year":"2019","unstructured":"Follman S, et al. Naloxone prescriptions among commercially insured individuals at high risk of opioid overdose. JAMA Netw Open. 2019;2(5):e193209.","journal-title":"JAMA Netw Open."},{"issue":"5","key":"923_CR5","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1001\/jama.2019.7988","volume":"322","author":"CM Jones","year":"2019","unstructured":"Jones CM, et al. naloxone co-prescribing to patients receiving prescription opioids in medicare part D program. United States, 2016\u20132017. JAMA. 2019;322(5):462\u20134.","journal-title":"JAMA."},{"key":"923_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-019-05405-9","author":"D Kispert","year":"2019","unstructured":"Kispert D, et al. Differences in naloxone prescribing by patient age, ethnicity, and clinic location among patients at high-risk for opioid overdose. J Gen Intern Med. 2019. https:\/\/doi.org\/10.1007\/s11606-019-05405-9.","journal-title":"J Gen Intern Med."},{"issue":"2","key":"923_CR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s11606-019-05423-7","volume":"35","author":"LA Lin","year":"2019","unstructured":"Lin LA, et al. Association of opioid overdose risk factors and naloxone prescribing in US adults. J Gen Intern Med. 2019;35(2):420\u20137.","journal-title":"J Gen Intern Med."},{"key":"923_CR8","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1056\/NEJMp1609578","volume":"375","author":"R Gupta","year":"2016","unstructured":"Gupta R, Shah ND, Ross JS. The rising price of naloxone\u2014risks to efforts to stem overdose deaths. N Engl J Med. 2016;375:2213\u20135.","journal-title":"N Engl J Med."},{"key":"923_CR9","unstructured":"Kirzinger A, et al. KFF health tracking poll\u2014February 2019: prescription drugs. 2019. https:\/\/www.kff.org\/health-costs\/poll-finding\/kff-health-tracking-poll-february-2019-prescription-drugs\/. Accessed 29 Jan 2020."},{"key":"923_CR10","doi-asserted-by":"publisher","first-page":"633","DOI":"10.7326\/0003-4819-153-10-201011160-00005","volume":"153","author":"WH Shrank","year":"2010","unstructured":"Shrank WH, et al. The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med. 2010;153:633\u201340.","journal-title":"Ann Intern Med."},{"issue":"6","key":"923_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/AJP.0b013e318169d03b","volume":"24","author":"M Von Korff","year":"2008","unstructured":"Von Korff M, et al. De Facto long-term opioid therapy for noncancer pain. Clin J Pain. 2008;24(6):521\u20137.","journal-title":"Clin J Pain."},{"issue":"6","key":"923_CR12","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1185\/03007995.2013.791617","volume":"29","author":"S Mercadente","year":"2013","unstructured":"Mercadente S, et al. Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin. 2013;29(6):661\u20136.","journal-title":"Curr Med Res Opin."},{"key":"923_CR13","unstructured":"The Network for Public Health Law. Legal interventions to reduce overdose mortality: naloxone access and overdose good samaritan laws. 2018. https:\/\/nosorh.org\/wp-content\/uploads\/2017\/05\/state-laws-naloxone.pdf. Accessed 29 Jan 2020."},{"issue":"23","key":"923_CR14","first-page":"631","volume":"64","author":"E Wheeler","year":"2015","unstructured":"Wheeler E, et al. Opioid overdose prevention programs providing naloxone to laypersons\u2014United States 2014. MMWR. 2015;64(23):631\u20135.","journal-title":"MMWR."},{"key":"923_CR15","unstructured":"Narcan. In: RED BOOK [database on the Internet]. http:\/\/www.micromedexsolutions.com. Accessed 29 Jan 2020."},{"key":"923_CR16","unstructured":"Evzio. In: RED BOOK [database on the Internet]. http:\/\/www.micromedexsolutions.com. Accessed 29 Jan 2020."},{"key":"923_CR17","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1056\/NEJMc1711899","volume":"377","author":"CV Dave","year":"2017","unstructured":"Dave CV, Hartzema A, Kesselheim AS. Prices of generic drugs associated with numbers of manufacturers. N Engl J Med. 2017;377:2597\u20138.","journal-title":"N Engl J Med."},{"key":"923_CR18","unstructured":"Food and Drug Administration. Press Release: FDA approves first generic naloxone nasal spray to treat opioid overdose. 2019. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-generic-naloxone-nasal-spray-treat-opioid-overdose. Accessed 29 Jan 2020."},{"key":"923_CR19","unstructured":"Kaleo News. Authorized generic for Evzio (naloxone HCl injection) to be available at reduced list price of $178. 2018. https:\/\/kaleo.com\/in-the-news\/authorized-generic-for-evzio-naloxone-hcl-injection-to-be-available-at-a-reduced-list-price-of-178\/. Accessed 19 Feb 2020."},{"key":"923_CR20","unstructured":"Food and Drug Administration. Adapt-Emergent Presentation for the December 17\u201318, 2018 Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Risk Management Advisory Committee. 2018. https:\/\/www.fda.gov\/media\/121188\/download. Accessed 29 Jan 2020."},{"key":"923_CR21","unstructured":"Food and Drug Administration. FDA presentations for the December 17\u201318, 2018 Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Risk Management Advisory Committee. 2018. https:\/\/www.fda.gov\/media\/121189\/download. Accessed 29 Jan 2020."},{"key":"923_CR22","unstructured":"Hicks J. People with this insurance can get the overdose reversal drug for free starting in January. 2017. https:\/\/www.vice.com\/en_us\/article\/j5dgxx\/aetna-narcan-no-copay. Accessed 29 Jan 2020."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00923-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-020-00923-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00923-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T01:03:57Z","timestamp":1615856637000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-020-00923-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,16]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["923"],"URL":"https:\/\/doi.org\/10.1007\/s40264-020-00923-6","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,16]]},"assertion":[{"value":"16 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Rachel Barenie serves as a clinical consultant to Alosa Health for opioid use disorder and pain management-related work. Joshua Gagne has received salary support from grants from Eli Lilly and Company and Novartis Pharmaceuticals Corporation and was a consultant to Aetion, Inc, and Optum, Inc., all for unrelated work. Aaron Kesselheim reports serving as an expert witness for the class of state plaintiffs in the multidistrict opiate litigation (2018\u20132019). Jing Luo has served as a clinical consultant to Alosa Health for opioid use disorder and pain management-related work. Jing Luo is now an Assistant Professor of Medicine at the University of Pittsburgh in Pittsburgh, PA and receives research support from the National Center For Advancing Translational Sciences of the National Institutes of Health under Award Number KL2TR001856. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Veterans Affairs. Brian Bateman serves as a consultant to Alosa Health for opioid use disorder and pain management-related work and Aetion, Inc and Merck for Mothers for unrelated work. Brian Bateman is a co-investigator on grants to his institution from Eli Lilly, GSK, Pfizer, Pacira, and Baxalta. Ajinkya Pawar and Angela Tong have no conflicts of interest that are directly relevant to the content of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Brigham and Women\u2019s Hospital waived the need for informed consent for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}